Comments on: Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Comments on: Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC https://www.novumpr.nl/2019/08/02/updated-real-world-data-shows-giotrif-gilotrif-afatinib-followed-by-osimertinib-provided-a-median-overall-survival-of-up-to-almost-four-years-in-patients-with-egfr-del19-and-t790m-mutati/?utm_source=rss&utm_medium=rss&utm_campaign=updated-real-world-data-shows-giotrif-gilotrif-afatinib-followed-by-osimertinib-provided-a-median-overall-survival-of-up-to-almost-four-years-in-patients-with-egfr-del19-and-t790m-mutati NovumPR press releases Fri, 02 Aug 2019 10:36:53 +0000 hourly 1 https://wordpress.org/?v=6.8.2